This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-24 and is reviewed periodically as new material appears.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
In this novel, Yourcenar recreated the life and death of one of the great rulers of the ancient world, the Roman emperor Hadrian, who writes a long letter to Marcus Aurelius, the son and heir of Antoninus Pius, his successor and adoptive son. Hadrian meditates on his past, describing both his triumphs and his failures, his love for Antinous, and his philosophy. The novel has become a modern classic. The English version was translated by Frick. In 1980, Yourcenar became the first female member elected to the Académie française. An anecdote tells of how the bathroom labels were then changed in this male-dominated institution: "Messieurs|Marguerite Yourcenar" (Gents/Marguerite Yourcenar). She published many novels, essays, and poems, as well as a trilogy of memoirs. At the time of her death, she was working on the third volume, titled Quoi? L'Eternité. Yourcenar's house on Mount Desert Island, Petite Plaisance, is now a museum dedicated to her memory. She is buried across the sound in Somesville.
=== Phenazines === Phenazines are redox-active pigments produced by P. aeruginosa. These pigments are involved in quorum sensing, virulence, and iron acquisition. P. aeruginosa produces several pigments all by the same biosynthetic pathway: phenazine-1-carboxamide (PCA), 1-hydroxyphenazine, 5-methylphenazine-1-carboxylic acid betaine, pyocyanin and aeruginosin A. Two nearly identical operons are involved in phenazine biosynthesis: phzA1B1C1D1E1F1G1 and phzA2B2C2D2E2F2G2. The enzymes encoded by these operons convert chorismic acid to PCA. The products of three key genes, phzH, phzM, and phzS then convert PCA to the other phenazines mentioned above. Though phenazine biosynthesis is well studied, questions remain as to the final structure of the brown phenazine pyomelanin. When pyocyanin biosynthesis is inhibited, a decrease in P. aeruginosa pathogenicity is observed in vitro. It has therefore been suggested that pyocyanin is mostly responsible for the initial colonization of P. aeruginosa in vivo.
=== Pharmacokinetics === Gepotidacin is rapidly absorbed orally, reaching peak plasma concentrations (tmax) after approximately 2.0 hours. In adults with uncomplicated urinary tract infections (uUTI) and normal renal function, the mean steady-state maximum concentration (Cmax) is 4.2 mcg/mL, and the area under the concentration-time curve over 12 hours AUC(0-12) is 22.8 mcg*hour/mL following a 1500 mg dose every 12 hours. Systemic exposure (Cmax and AUC) increases proportionally with dose. Accumulation of approximately 40% occurs and achieves a steady state by day 3. The absolute bioavailability is about 45%, and standard and moderate fat meals did not significantly affect its absorption. Gepotidacin's pharmacokinetics were found to be generally consistent across different ages, sexes, races, and body weights during modeling and simulation. Gepotidacin has a mean steady-state volume of distribution (Vss) of 172.9 liters and is 25-41% bound to plasma proteins. It has a terminal elimination half-life of approximately 9.3 hours and a total clearance of 33.4 L/hour. The primary metabolic pathway involves CYP3A4, with a minor metabolite (M4, ~11% of circulating drug). The co-administration of other drugs can influence gepotidacin levels. Strong inhibitors of CYP3A4 can increase gepotidacin exposure, whereas strong inducers of CYP3A4 can decrease it. Additionally, gepotidacin, at high concentrations, has shown the potential to increase the exposure of certain other drugs, including digoxin and midazolam.
== Career == In 1979, Weber joined the Department of Chemistry at the University of Pittsburgh, where he is currently a Professor of Chemistry and Clinical Translational Science. He has served in a number of capacities at the university, including becoming Director of Graduate Studies for the Chemistry Department in 2001. He has published over 200 journal articles, and has served on the editorial boards of Analytical Chemistry, Trends in Analytical Chemistry and the Journal of Chromatography.
Sources: en.wikipedia.org
cytoplasm All of the material contained within a cell excluding (in eukaryotes) the nucleus; i.e. that part of the protoplasm which is enclosed by the plasma membrane but separated from the nucleoplasm by the nuclear envelope, consisting of the fluid cytosol and the totality of its contents, including all of the cell's internal compartments, organelles, and substructures such as mitochondria, lysosomes, the endoplasmic reticulum, vesicles and inclusions, and a network of filamentous microtubules known as the cytoskeleton. Some definitions of cytoplasm exclude certain organelles such as vacuoles and plastids. Composed of about 80 percent water, the numerous small molecules and macromolecular complexes dissolved or suspended within the cytoplasm give it characteristic viscoelastic and thixotropic properties, allowing it to behave variously as a gel or a liquid solution. Though continuous throughout the intracellular space, the cytoplasm can often be resolved into distinct phases of different density and composition, such as an endoplasm and ectoplasm. Most of the metabolic and biosynthetic activities of the cell take place in the cytoplasm, including protein synthesis by ribosomes. Despite their physical separation, the cytoplasm and the nucleus are mutually dependent upon each other, such that an isolated nucleus without cytoplasm is as incapable of surviving for long periods as is the cytoplasm without a nucleus.
=== Early years === Sidney Fox was the son of Jacob Fox, a wig-maker, and Louise Berman, a Ukrainian immigrant. Fox married Raia Joffe Fox and they had three sons: Lawrence, Ronald, and Thomas. All three of his sons became scientists. His family was Jewish. Fox obtained a Bachelor of Arts degree from University of California, Los Angeles in Chemistry. He went on to earn a Ph.D. from California Institute of Technology in 1940 and did his postdoctoral work at the Linus Pauling Laboratory where he grew close with Linus Pauling.
continuity (conservation of mass), conservation of linear momentum, conservation of angular momentum, conservation of energy. The study of fluids is fluid mechanics, which is subdivided into fluid dynamics and fluid statics depending on whether the fluid is in motion.
== See also == Le Grand Saut Lockheed U-2 Overshooting top Ozone depletion Batterie Pommern (the first projectile to reach the lower stratosphere) Paris Gun (projectile was the first artificial object to reach the upper stratosphere) Perlan Project Project Excelsior, world record for highest recorded jump 1961–2012 Red Bull Stratos, world record for highest recorded jump 2012–2014 RQ-4 Global Hawk Service ceiling Upper-atmospheric lightning Sudden stratospheric warming
== How to determine GR == The index is derived from a mathematical model of insulin-glucose homeostasis that incorporates fundamental physiological motifs. For diagnostic purposes, it is calculated from fasting insulin and glucose concentrations with:
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.